Gilead Sciences

GILD 62.25
0.00 (0.0%)

Open: 62.10 High: 62.51 Low: 61.77

9 x 62.25 = 560.25
x $62.25 =

NASDAQ: GILD $82 Billion Large-Cap. Nasdaq 100. S&P 500. Health Care Sector. Biotech & Pharma Industry. 5 Year Return 38%. 1 Year Return 2%. 2020 YTD Return 3%. Negative 5 year, 1 year & YTD returns. 3.4% dividend yield. 15 total dividend payments. Since Earnings 14%. "Possible" Death Cross chart pattern.

ST

External Links

Free Channels & more...

For Starters

Charts

image
image

52WL $61.52

The 52 Week Low is $61.52 set on Wed, Oct 2, 2019.

52WH $85.67

The 52 Week High is $85.67 set on Thu, Apr 30, 2020.

ATH $122.40

The All-Time High is $122.40 set on Tue, Jun 23, 2015.

52 Week Range

$61.52
$85.67
Oct 2, 2019
Apr 30, 2020

Earnings

-2.66

Earnings Per Share

55.20

Price To Earnings Ratio


Q1 Earnings for Jan, Feb & Mar

Thu, Apr 30, 2020

Since Q1 Earnings Report

GILD 25.1%


Q2 Earnings for Apr, May & Jun

Thu, Jul 30, 2020

Since Q2 Earnings Report

GILD 14.7%

Dividends

3.37

Dividend Yield

2.28

Dividend Rate

Thu, Dec 13, 2018

Ex-Dividend Date

Fri, Dec 28, 2018

Dividend Payment Date

Quarterly

Dividend Frequency

15

Dividend History

Profile

Gilead Sciences trades on the NASDAQ. GILD's market cap is 78.0 Billion.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Website

Related Channels

Account Channels

Track your portfolio and more.